Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants

By Ehrenpreis Eli D   Sifuentes Humberto   Ehrenpreis Jamie E   Smith Zachary L   Marshall Mike L  

Expert Opinion on Drug Safety, Vol. 11, Iss. 2, 2012-03 ,pp. : 177-183

Informa Healthcare

Access to resources Recommend Favorite

Statistical Methods to Analyze Adverse Events Data of Randomized Clinical Trials

By Siddiqui Ohidul  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 5, 2009-09 ,pp. : 889-899

Taylor & Francis Ltd

Access to resources Recommend Favorite

`Extreme Duplication' in the US FDA Adverse Events Reporting System Database

By Hauben Manfred   Reich Lester   DeMicco James   Kim Katherine  

Drug Safety, Vol. 30, Iss. 6, 2007-01 ,pp. : 551-554

Adis International

Access to resources Recommend Favorite

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis

By Wen Warren  

Expert Opinion on Drug Safety, Vol. 12, Iss. 3, 2013-05 ,pp. : 309-319

Informa Healthcare

Access to resources Recommend Favorite

Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database: A Disproportionality Analysis

By Shamloo Behrooz K.  

Drug Safety, Vol. 35, Iss. 6, 2012-06 ,pp. : 507-518

Adis International

Access to resources Recommend Favorite